TFF Pharmaceuticals (TFFP) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Document Information Line Items
Entity Registrant Name	TFF PHARMACEUTICALS, Inc.
Trading Symbol	TFFP
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		25,518,084
Amendment Flag	false
Entity Central Index Key	0001733413
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39102
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4344737
Entity Address, Address Line One	1751 River Run
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76107
City Area Code	(817)
Local Phone Number	438-6168
Title of 12(b) Security	Common stock: Par value $0.001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,147,090	$ 33,794,672
Receivable due from collaboration agreement	1,812,975	1,628,703
Research and development tax incentive receivable	949,168	966,646
Prepaid assets and other current assets	1,069,761	2,447,930
Total current assets	16,978,994	38,837,951
Operating lease right-of-use asset, net	214,264
Property and equipment, net	3,026,466	1,859,860
Other assets	7,688
Total assets	20,227,412	40,697,811
Current liabilities:
Accounts payable	1,634,024	1,493,842
Accrued compensation		416,910
Deferred research grant revenue	362,710	50,000
Current portion of operating lease liability	79,838
Total current liabilities	2,076,572	1,960,752
Operating lease liability, net of current portion	128,314
Total liabilities	2,204,886	1,960,752
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,518,084 and 25,371,781 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	25,518	25,372
Additional paid-in capital	107,922,543	104,078,968
Accumulated other comprehensive loss	(210,347)	(48,921)
Accumulated deficit	(89,715,188)	(65,318,360)
Total stockholders’ equity	18,022,526	38,737,059
Total liabilities and stockholders’ equity	$ 20,227,412	$ 40,697,811

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	25,518,084	25,371,781
Common stock, shares outstanding	25,518,084	25,371,781

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Grant revenue	$ 87,586	$ 50,000	$ 183,025	$ 76,165
Operating expenses:
Research and development	4,025,940	6,339,993	14,360,293	14,380,415
General and administrative	3,342,266	2,387,585	10,238,744	7,386,007
Total operating expenses	7,368,206	8,727,578	24,599,037	21,766,422
Loss from operations	(7,280,620)	(8,677,578)	(24,416,012)	(21,690,257)
Other income (expense):
Other income		(13,129)		659,695
Interest income	6,119	12,051	19,184	41,619
Total other income (expense), net	6,119	(1,078)	19,184	701,314
Net loss	$ (7,274,501)	$ (8,678,656)	$ (24,396,828)	$ (20,988,943)
Net loss per share, basic and diluted (in Dollars per share)	$ (0.29)	$ (0.34)	$ (0.96)	$ (0.85)
Weighted average common shares outstanding, basic and diluted (in Shares)	25,451,691	25,371,781	25,399,352	24,635,350
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (7,274,501)	$ (8,678,656)	$ (24,396,828)	$ (20,988,943)
Other comprehensive loss:
Foreign currency translation adjustments	(103,226)	(53,498)	(161,426)	(118,790)
Comprehensive loss	$ (7,377,727)	$ (8,732,154)	$ (24,558,254)	$ (21,107,733)

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net loss per share, basic and diluted (in Dollars per share)	$ (0.29)	$ (0.34)	$ (0.96)	$ (0.85)
Weighted average common shares outstanding, basic and diluted (in Shares)	25,451,691	25,371,781	25,399,352	24,635,350

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 22,535	$ 71,648,453	$ (51,538)	$ (34,279,648)	$ 37,339,802
Balance (in Shares) at Dec. 31, 2020	22,534,874
Issuance of common stock for stock option exercises	$ 245	655,008			655,253
Issuance of common stock for stock option exercises (in Shares)	244,656
Sale of common stock, net of offering costs	$ 2,140	28,021,424			28,023,564
Sale of common stock, net of offering costs (in Shares)	2,140,000
Issuance of common stock for warrant exercises	$ 444	179,768			180,212
Issuance of common stock for warrant exercises (in Shares)	444,751
Stock-based compensation		1,030,415			1,030,415
Foreign currency translation adjustment			(37,958)		(37,958)
Net loss				(7,654,575)	(7,654,575)
Balance at Mar. 31, 2021	$ 25,364	101,535,068	(89,496)	(41,934,223)	59,536,713
Balance (in Shares) at Mar. 31, 2021	25,364,281
Balance at Dec. 31, 2020	$ 22,535	71,648,453	(51,538)	(34,279,648)	37,339,802
Balance (in Shares) at Dec. 31, 2020	22,534,874
Net loss					(20,988,943)
Balance at Sep. 30, 2021	$ 25,372	103,158,144	(170,328)	(55,268,591)	47,744,597
Balance (in Shares) at Sep. 30, 2021	25,371,781
Balance at Mar. 31, 2021	$ 25,364	101,535,068	(89,496)	(41,934,223)	59,536,713
Balance (in Shares) at Mar. 31, 2021	25,364,281
Additional offering costs related to the sale of common stock		(8,545)			(8,545)
Issuance of common stock for stock option exercises	$ 8	34,492			34,500
Issuance of common stock for stock option exercises (in Shares)	7,500
Stock-based compensation		740,535			740,535
Foreign currency translation adjustment			(27,334)		(27,334)
Net loss				(4,655,712)	(4,655,712)
Balance at Jun. 30, 2021	$ 25,372	102,301,550	(116,830)	(46,589,935)	55,620,157
Balance (in Shares) at Jun. 30, 2021	25,371,781
Stock-based compensation		856,594			856,594
Foreign currency translation adjustment			(53,498)		(53,498)
Net loss				(8,678,656)	(8,678,656)
Balance at Sep. 30, 2021	$ 25,372	103,158,144	(170,328)	(55,268,591)	47,744,597
Balance (in Shares) at Sep. 30, 2021	25,371,781
Balance at Dec. 31, 2021	$ 25,372	104,078,968	(48,921)	(65,318,360)	38,737,059
Balance (in Shares) at Dec. 31, 2021	25,371,781
Stock-based compensation		1,177,702			1,177,702
Foreign currency translation adjustment			47,234		47,234
Net loss				(8,376,002)	(8,376,002)
Balance at Mar. 31, 2022	$ 25,372	105,256,670	(1,687)	(73,694,362)	31,585,993
Balance (in Shares) at Mar. 31, 2022	25,371,781
Balance at Dec. 31, 2021	$ 25,372	104,078,968	(48,921)	(65,318,360)	$ 38,737,059
Balance (in Shares) at Dec. 31, 2021	25,371,781
Issuance of common stock for stock option exercises (in Shares)
Net loss					$ (24,396,828)
Balance at Sep. 30, 2022	$ 25,518	107,922,543	(210,347)	(89,715,188)	18,022,526
Balance (in Shares) at Sep. 30, 2022	25,518,084
Balance at Mar. 31, 2022	$ 25,372	105,256,670	(1,687)	(73,694,362)	31,585,993
Balance (in Shares) at Mar. 31, 2022	25,371,781
Issuance of common stock for stock option exercises	$ 2	10,183			10,185
Issuance of common stock for stock option exercises (in Shares)	2,037
Stock-based compensation		1,195,081			1,195,081
Foreign currency translation adjustment			(105,434)		(105,434)
Net loss				(8,746,325)	(8,746,325)
Balance at Jun. 30, 2022	$ 25,374	106,461,934	(107,121)	(82,440,687)	23,939,500
Balance (in Shares) at Jun. 30, 2022	25,373,818
Issuance of common stock for stock option exercises	$ 40	100,597			100,637
Issuance of common stock for stock option exercises (in Shares)	40,255
Sale of common stock, net of offering costs	$ 104	404,451			404,555
Sale of common stock, net of offering costs (in Shares)	104,011
Stock-based compensation		955,561			955,561
Foreign currency translation adjustment			(103,226)		(103,226)
Net loss				(7,274,501)	(7,274,501)
Balance at Sep. 30, 2022	$ 25,518	$ 107,922,543	$ (210,347)	$ (89,715,188)	$ 18,022,526
Balance (in Shares) at Sep. 30, 2022	25,518,084

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (24,396,828)	$ (20,988,943)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	3,328,344	2,627,544
Depreciation and amortization	267,311	34,426
Changes in operating assets and liabilities:
Receivable due from collaboration agreement	(184,272)	(831,061)
Research and development tax incentive receivable	(103,307)	(1,168,553)
Prepaid assets and other assets	1,433,966	1,407,862
Accounts payable	148,657	269,433
Accrued compensation	(416,910)
Deferred revenue	312,710	(24,315)
Operating lease obligation	(29,869)
Net cash used in operating activities	(19,640,198)	(18,673,607)
Cash flows from investing activities:
Purchases of property and equipment	(1,410,159)	(741,853)
Net cash used in investing activities	(1,410,159)	(741,853)
Cash flows from financing activities:
Net proceeds from issuance of common stock	404,555	28,015,019
Proceeds from issuance of common stock for stock option exercises	10,185	689,753
Proceeds from issuance of common stock for warrant exercises		180,212
Net cash provided by financing activities	414,740	28,884,984
Effect of exchange rate changes on cash and cash equivalents	(11,965)	(54,586)
Net change in cash and cash equivalents	(20,647,582)	9,414,938
Cash and cash equivalents at beginning of period	33,794,672	35,300,805
Cash and cash equivalents at end of period	13,147,090	44,715,743
Supplemental disclosure of non-cash investing and financing activities:
Receivable for option exercise	100,637
Cashless exercise of warrants		416
ROU asset obtained under for new operating lease	$ 238,021

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2022
Organization and Description of Business [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS TFF Pharmaceuticals, Inc. (the “Company”) was incorporated in the State of Delaware on January 24, 2018. The Company’s initial focus is on the development of inhaled dry powder drugs to enhance the treatment of pulmonary diseases and conditions. In December 2019, the Company established a wholly owned Australian subsidiary, TFF Pharmaceuticals Australia Pty Ltd (“TFF Australia”), in order to conduct clinical research. TFF Pharmaceuticals, Inc., along with TFF Australia, are collectively referred to as the “Company”. The Company is in the development stage and is devoting substantially all of its efforts toward technology research and development and the human clinical trials of its initial product candidates.

Liquidity and Management_s Plan

Liquidity and Management’s Plans	9 Months Ended
	Sep. 30, 2022
Liquidity and Managements Plans [Abstract]
LIQUIDITY AND MANAGEMENT’S PLANS	NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLANS For the three and nine months ended September 30, 2022, the Company reported a net loss of $7.3 million and $24.4 million, respectively, and negative cash flow from operations for the nine months ended September 30, 2022 of $19.6 million. The Company had an accumulated deficit of $89.7 million and cash and cash equivalents of $13.1 million as of September 30, 2022. The Company has not generated revenues from commercial operations since inception and expects to continue incurring losses for the foreseeable future and needs to raise additional capital to continue the pursuit of its product development. On June 10, 2022, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as agent, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $35.0 million in an “at-the-market” (“ATM”) offering, to or through the agent. Through September 30, 2022, the Company sold 104,011 shares of its common stock at average price of $5.96 per share resulting in net proceeds of approximately $405,000, after deducting sales agent commissions and offering expenses. The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to September 30, 2022. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it hires additional professional and scientific staff and continues to prepare for anticipated manufacturing activities. If the Company encounters unforeseen delays or expenses, it has the ability to curtail its presently planned level of operations. The Company plans to seek additional funding through various financing sources, including the sale of its equity and/or debt securities, and/or licensing fees for its technology and co-development and joint ventures with industry partners. The Company believes that its current cash and cash equivalents, and its access to capital through the sale of its equity securities, including the ATM offering, are sufficient to fund its present plan of operations for the next 12 months from the date of filing of these condensed consolidated financial statements. In addition, the Company will consider alternatives to its current business plan that may enable it to achieve its product development goals with a smaller amount of capital.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Summary of Significant Accounting Policies [Line Items]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2022 and the results of operations, changes in stockholders’ equity and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Reclassification Certain prior period amounts have been reclassified to conform to the current period classification. Amounts received from the United States Internal Revenue Service (“IRS”) for payroll tax credits have been reclassified from other income to operating expenses in the condensed consolidated statements of operations to net the amounts with the related expense that was incurred with no changes in the previously reported net losses. Principles of Consolidation The consolidated financial statements include the accounts of TFF Pharmaceuticals, Inc. and its wholly owned subsidiary, TFF Australia. All material intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency The currency of TFF Australia, the Company’s international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate component of stockholders’ equity in accumulated other comprehensive loss. Cash and Cash Equivalents The Company maintains its operating accounts in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. At times, the Company’s cash balances may be uninsured for deposit accounts that exceed insured limits. The Company has not experienced any losses on such accounts. The Company’s cash is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of September 30, 2022 and December 31, 2021, the Company had cash in Australia of AUD$59,664 (US$38,376) and AUD$831,984 (US$604,944), respectively. Leases At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one year are recognized on the condensed consolidated balance sheets as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the condensed consolidated balance sheets leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Revenue Recognition The Company has entered into feasibility and material transfer agreements (“Feasibility Agreements”) with third parties that provide the Company with funds in return for certain research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met. The Feasibility Agreements are on a best-effort basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable. The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations. Funds received from the Feasibility Agreements are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements are part of the Company’s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. During the three months ended September 30, 2022 and 2021, the Company rendered the related services and recognized revenue and research and development expenses of $87,586 and $50,000, respectively. During the nine months ended September 30, 2022 and 2021, the Company rendered the related services and recognized revenue and research and development expenses of $183,025 and $76,165, respectively. As of September 30, 2022 and December 31, 2021, the Company had receivables due related to Feasibility Agreements of $232,296 and $11,996, respectively, which is included in prepaid assets and other current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of $362,710 and $50,000, respectively. Collaborative Arrangements The Company considers the nature and contractual terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under Accounting Standards Codification (“ASC”) 808, Collaborative Arrangements For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company’s consolidated balance sheets. Please refer to Note 5, “Joint Development Agreement” for additional details regarding the Company’s joint development agreement (“JDA”) with Augmenta Bioworks, Inc. (“Augmenta”). If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers Research and Development Tax Incentive The Company is eligible to obtain a cash refund from the Australian Taxation Office for eligible research and development expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during 2020 as other income in the condensed consolidated statements of operations during the period ended September 30, 2021. As the Company has determined that it has reasonable assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company’s ongoing tax status, or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for the periods ended September 30, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the IRS related to research and development tax credits for expenditures. The research and development incentive receivable represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development tax incentive receivable of $949,168 and $966,646 as of September 30, 2022 and December 31, 2021, respectively, in the condensed consolidated balance sheets. The Company recorded other income (expense) of $(13,129) and $659,695, in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021, respectively, related to refundable research and development incentive program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $25,544 and $103,307 during the three and nine months ended September 30, 2022, respectively, and $219,520 and $735,927 during the three and nine months ended September 30, 2021, respectively. Basic and Diluted Earnings per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. For the nine months ended September 30, 2022 and 2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted net loss per common share because inclusion thereof would be anti-dilutive: Nine Months Ended September 30, 2022 2021 Stock Options 2,866,439 2,723,339 Warrants 414,233 389,233 3,280,672 3,112,572 Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates. Risks and Uncertainties In December 2019, COVID-19, a novel strain of coronavirus, was first identified in China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Potential impacts to the Company’s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the supply of comparator products, the potential diversion of healthcare resources and staff away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company’s ability to raise capital and conduct business development activities. The Company has experienced COVID-19 related delays in its Phase 2 clinical trials for TFF Voriconazole Inhalation Powder (“TFF Vori”) and TFF Tacrolimus Inhalation Powder (“TFF Tac-Lac”). While the Company believes it will be able to effectively manage the delays, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19. Recent Accounting Standards There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the nine months ended September 30, 2022 that are of significance or potential significance to the Company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4 - COMMITMENTS AND CONTINGENCIES Operating Leases In October 2018, the Company entered into a lease agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018 and expires on October 31, 2023, as amended. The lease has an additional one-year option for renewal, and the base rent is $36,000 per year through October 31, 2022 and increases to $37,080 per year through October 31, 2023. The Company has determined that the lease agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The Company rents another office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease as well. In May 2022, the Company entered into a lease agreement for lab space in Austin, Texas. The lease commenced on June 1, 2022 and expires on May 31, 2025. The lease has an additional three-year option for renewal, which the Company has determined it is not reasonably certain to exercise. Supplemental balance sheet information related to leases was as follows: September 30, Operating leases:  Operating lease right-of-use assets $ 214,264 Operating lease liability – current portion $ 79,838 Operating lease liability – long-term portion 128,314 Total operating lease liabilities $ 208,152 Supplemental lease expense related to leases was as follows: Statement of Operations For The Three Months Ended September 30, For The Nine Months Ended September 30, Lease Classification 2022 2021 2022 2021 Operating lease cost Research and development $ 22,275 $ - $ 29,700 $ - Short-term lease cost Research and development 6,244 11,000 18,733 27,000 Short-term lease cost General and administrative 21,000 9,000 62,659 27,000 Total lease expense $ 49,519 $ 20,000 $ 111,092 $ 54,000 Other information related to operating leases: September 30, Weighted-average remaining lease term 2.7 years Weighted-average discount rate 8 % Supplemental cash flow information related to operating leases was as follows: For The Nine Months Ended September 30, 2022 2021 Cash paid for operating lease liabilities $ 29,869 $ - Approximate future minimum lease payments under non-cancellable leases (including short-term leases) are as follows: Fiscal Year Ending December 31, 2022 (Remaining) $ 24,000 2023 119,000 2024 91,000 2025 38,000 Total minimum lease payments 272,000 Less: Imputed interest (23,000 ) Total $ 249,000 Legal The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition. To the Company’s knowledge, neither the Company nor any of its properties are subject to any pending legal proceedings.

License and Agreements

License and Agreements	9 Months Ended
	Sep. 30, 2022
License And Agreement Disclosure Abstract
LICENSE AND AGREEMENTS	NOTE 5 - LICENSE AND AGREEMENTS In July 2015, the University of Texas at Austin (“UT”) granted to the Company’s former parent, LTI, an exclusive worldwide, royalty bearing license to the patent rights for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide, royalty bearing license to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all of its interest to the TFF platform, including the patent license agreement with UT, at which time the Company paid UT an assignment fee of $100,000 in accordance with the patent license agreement. In November 2018, the Company and UT entered into an amendment to the patent license agreement pursuant to which, among other things, the Company’s exclusive patent rights to the TFF platform were expanded to all fields of use, and in March 2022 the Company and UT entered into an amended and restated patent license agreement for purposes of further strengthening the Company’s license rights, including the Company’s exclusive right to license all future UT patents relating to the TFF technology and all know-how held by UT relating to the TFF technology . The patent license agreement requires the Company to pay royalties and milestone payments and conform to a variety of covenants and agreements, and in the event of the Company’s breach of agreement, UT may elect to terminate the agreement. For the period ended December 31, 2018, the Company did not achieve any of the milestones and, as such, was not required to make any milestone payments. During the ended December 31, 2019, the Company achieved one milestone by gaining IND approval on first indication of a licensed product on November 24, 2019 and the Company satisfied the milestone payment of $50,000 and issuance of shares in accordance with the agreement. As of the date of these condensed consolidated financial statements, the Company is in compliance with the patent license agreement as all required amounts have been paid in accordance with the agreement. In May 2018, the Company entered into a master services agreement and associated individual study contracts with ITR Canada, Inc. (“ITR”) to provide initial contract pre-clinical research and development services for the Company’s drug product candidates. In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract with SPI were sub-contracted to ITR and others under substantially the same terms as the initial contract with ITR. Desire Ventures, LLC facilitates the invoicing for the various affiliates. The accounts payable due in connection with this agreement was $0 as of both September 30, 2022 and December 31, 2021. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately $41,000 and $2,358,000, respectively, pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately $0 and $2,380,000, respectively, pertaining to this agreement. In April 2019, the Company entered into a master services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company’s drug product candidates, TFF Vori. The accounts payable due in connection with this agreement was approximately $0 and $21,000 as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately $209,000 and $835,000, respectively, pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately $639,000 and $1,436,000, respectively, pertaining to this agreement. In January 2020, TFF Australia entered into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$38,000 (US$24,000) and AUD$138,000 (US$100,000) as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately AUD$87,000 (US$59,000) and AUD$550,000 (US$388,000), respectively, pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately AUD$547,000 (US$402,000) and AUD$1,468,000 (US$1,113,000), respectively, pertaining to this agreement In May 2020, TFF Australia entered into an amended clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company’s drug candidates, TFF Tac-Lac. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company did not record any research and development costs pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately AUD$119,000 (US$87,000) and AUD$565,000 (US$429,000), respectively, pertaining to this agreement. On August 12, 2020, the Company entered into a licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide exclusive license for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION can exercise its option to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated trials. Upon exercise of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed product. The Company will be eligible to receive milestone payments upon the achievement of certain milestones in the development the licensed products, based on completion of clinical trials, pre-marketing approvals and/or the receipt of at least $25,000,000 of grant funding. The Company will receive a single-digit tiered royalty on net sales. The Company will also be entitled to receive sales-related milestone payments based on the commercial success of the licensed products. In January 2021, the Company entered into a master services agreement with Experic to provide contract manufacturing services for one of the Company’s drug product candidates, TFF Vori. The accounts payable due in connection with this agreement was approximately $133,000 and $313,000 as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately $643,000 and $1,223,000, respectively, pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately $735,000 and $1,036,000, respectively, pertaining to this agreement. In January 2022, the Company entered into a Letter of Intent with Synteract, Inc. to provide contract research and development services, which was replaced by a Master Services Agreement entered into in May 2022, for one of the Company’s drug product candidates, TFF Vori. The accounts payable due in connection with this agreement was approximately $363,000 as of September 30, 2022. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately $800,000 and $2,099,000, respectively, pertaining to this agreement. Joint Development Agreement On November 2, 2020, the Company and Augmenta entered into the JDA pursuant to which the Company and Augmenta (collectively the “Parties”) agreed to work jointly to develop one or more novel commercial products incorporating Augmenta’s human derived monoclonal antibody for the treatment of patients with COVID-19 and the Company’s patented Thin Film Freezing technology platform. Each party retains full ownership over its existing assets. The Parties will share development costs with each party funding its fifty-percent share at specified times. In the event that one of the Parties fails to make its pro rata share payment, the other party may terminate the JDA. In lieu of terminating the JDA, the non-defaulting party may elect to continue the JDA by paying the delinquent amount and each party’s pro rata share of the JDA will automatically adjust by the amount paid. In addition, in the event Augmenta experiences a default on its required payment, Augmenta will have the one-time right to elect to require the Company to purchase Augmenta’s interest in the JDA (“Put Right”) for a one-time fee of $500,000. Upon exercise of the Put Right and payment by the Company, Augmenta will grant the Company an exclusive, worldwide, royalty-free, transferable, sublicensable license to the Augmenta antibody and Augmenta’s rights to the property developed under the JDA. The Company has determined that the likelihood of the Put Right being exercised to be remote. The JDA is within the scope of ASC 808 as the Company and Augmenta are both active participants in the research and development activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The research and development activities are a unit of account under the scope of ASC 808 and are not promises to a customer under the scope of ASC 606. The Company records its portion of the research and development expenses as the related expenses are incurred. All payments received or amounts due from Augmenta for reimbursement of shared costs are accounted for as an offset to research and development expense. During the three and nine months ended September 30, 2022, the Company recorded research and development expenses of $0 and $184,273, respectively. During the three and nine months ended September 30, 2021, the Company recorded research and development expenses of $341,840 and $828,511, respectively. The Company has recorded a receivable of $1,812,975 and $1,628,703 for reimbursement due from Augmenta as of September 30, 2022 and December 31, 2021, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 6 - STOCKHOLDERS’ EQUITY Common Stock Stock Option Exercises During the nine months ended September 30, 2022, 42,292 shares of common stock were issued in connection with the exercise of stock options for total proceeds of $110,822, including $100,637 that was included in prepaid assets and other current assets as of September 30, 2022 and was received in October 2022. At-Market-Offering On June 10, 2022, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as agent, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $35.0 million in an ATM offering, to or through the agent. Through September 30, 2022, the Company sold 104,011 shares of its common stock at average price of $5.96 per share resulting in net proceeds of approximately $405,000, after deducting offering expenses.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 7 - STOCK-BASED COMPENSATION In January 2018, the Company’s board of directors approved its 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock, the grant of restricted and unrestricted share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the 2018 Plan; however, upon completion of the Company’s IPO the number of shares reserved for issuance under the 2018 Plan increased to 3,284,480, representing 15% of the Company’s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the Company’s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company’s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan. In September 2021, the Company’s board of directors approved its 2021 Stock Incentive Plan (“2021 Plan”), which was also approved by the stockholders of the Company at the Company’s annual meeting of stockholders held on November 4, 2021. The 2021 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock, the grant of restricted and unrestricted share awards and grant of restricted stock units. The Company has 4,200,000 shares of its common stock reserved under the 2021 Plan. All of the Company’s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company’s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible to receive incentive awards under the 2021 Plan. The following table summarizes the stock-based compensation expense recorded in the Company’s results of operations during the three and nine months ended September 30, 2022 and 2021 for stock options and warrants: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ 228,170 $ 137,549 $ 676,053 $ 274,285 General and administrative 727,391 719,045 2,652,291 2,353,259 $ 955,561 $ 856,594 $ 3,328,344 $ 2,627,544 As of September 30, 2022, there was approximately $6,708,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected to vest. This cost is expected to be recognized over a weighted-average period of 1.9 years. The Company records compensation expense for awards with graded vesting using the straight-line method. The Company recognizes compensation expense over the requisite service period applicable to each individual award, which generally equals the vesting term. The Company estimates the fair value of each option award using the Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized. The Company estimated the fair value stock options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service periods of the respective awards. The fair value of stock options issued was estimated using the following assumptions: Nine Weighted average exercise price $ 7.06 Weighted average grant date fair value $ 5.34 Assumptions Expected volatility 90%-97 % Weighted average expected term (in years) 6.3-10.0 Risk-free interest rate 2.41%-2.84 % Expected dividend yield 0.00 % The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was based upon the historical volatility for industry peers and used an average of those volatilities. The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity for employee awards and the contractual term for nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and does not expect to pay dividends in the foreseeable future. The Company uses the closing stock price on the date of grant as the fair value of the common stock The following table summarizes stock option activity during the nine months ended September 30, 2022: Number of Weighted- Weighted- Intrinsic Outstanding at January 1, 2022 2,893,839 $ 6.48 8.05 $ 9,932,413 Granted 135,000 7.06 — — Exercised (42,292 ) 2.62 — — Cancelled (120,108 ) 7.44 — — Outstanding at September 30, 2022 2,866,439 $ 6.53 7.41 $ 1,186,091 Exercisable at September 30, 2022 1,770,913 $ 5.37 6.88 $ 1,138,945 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had strike prices lower than the fair value of the Company’s common stock. The intrinsic value of the options exercised during 2022 was approximately $76,000. Option Modification Effective March 21, 2022, one of the members of the Company’s board of directors, Dr. Brian Windsor, resigned. As part of his resignation from the board of directors, modifications were made to Dr. Windsor’s vested and non-vested stock option awards including acceleration of certain non-vested option awards and the extension of the post-termination exercise period of certain stock option awards. During the nine months ended September 30, 2022, in accordance with ASC Topic 718, Compensation—Stock Compensation, Warrants On June 7, 2022, the Company issued a five-year warrant to purchase 25,000 shares of common stock at $5.70 per share to a consultant. The fair value of the warrant on the grant date was estimated using the Black-Scholes-Merton option pricing model with a common stock value of $5.74 per share, a contractual life of 5.0 years, a dividend yield of 0%, volatility of 96.87% and an assumed risk-free interest rate of 2.99%. The warrant is immediately exercisable. The fair value of the warrant was determined to be approximately $107,000 and was recorded in general and administrative expenses in the condensed consolidated statements of operations during the period ended September 30, 2022. In determining the fair value for warrants, the expected life of the Company’s warrants was determined using the contractual life. The methodology in determining all other inputs to calculate the fair value utilizing the Black-Scholes-Merton option pricing model is the same as the stock option methodology described above for stock options.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to September 30, 2022 through the filing date of this Quarterly Report. Based on its evaluation, nothing other than the events included in the notes to the condensed consolidated financial statements need to be disclosed.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2022
Organization and Description of Business [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2022 and the results of operations, changes in stockholders’ equity and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to the current period classification. Amounts received from the United States Internal Revenue Service (“IRS”) for payroll tax credits have been reclassified from other income to operating expenses in the condensed consolidated statements of operations to net the amounts with the related expense that was incurred with no changes in the previously reported net losses.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of TFF Pharmaceuticals, Inc. and its wholly owned subsidiary, TFF Australia. All material intercompany accounts and transactions have been eliminated in consolidation.
Foreign Currency	Foreign Currency The currency of TFF Australia, the Company’s international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate component of stockholders’ equity in accumulated other comprehensive loss.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its operating accounts in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. At times, the Company’s cash balances may be uninsured for deposit accounts that exceed insured limits. The Company has not experienced any losses on such accounts. The Company’s cash is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of September 30, 2022 and December 31, 2021, the Company had cash in Australia of AUD$59,664 (US$38,376) and AUD$831,984 (US$604,944), respectively.
Leases	Leases At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one year are recognized on the condensed consolidated balance sheets as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the condensed consolidated balance sheets leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
Revenue Recognition	Revenue Recognition The Company has entered into feasibility and material transfer agreements (“Feasibility Agreements”) with third parties that provide the Company with funds in return for certain research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met. The Feasibility Agreements are on a best-effort basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable. The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations. Funds received from the Feasibility Agreements are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements are part of the Company’s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. During the three months ended September 30, 2022 and 2021, the Company rendered the related services and recognized revenue and research and development expenses of $87,586 and $50,000, respectively. During the nine months ended September 30, 2022 and 2021, the Company rendered the related services and recognized revenue and research and development expenses of $183,025 and $76,165, respectively. As of September 30, 2022 and December 31, 2021, the Company had receivables due related to Feasibility Agreements of $232,296 and $11,996, respectively, which is included in prepaid assets and other current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of $362,710 and $50,000, respectively.
Collaborative Arrangements	Collaborative Arrangements The Company considers the nature and contractual terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts for such arrangement as a collaborative arrangement under Accounting Standards Codification (“ASC”) 808, Collaborative Arrangements For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company’s consolidated balance sheets. Please refer to Note 5, “Joint Development Agreement” for additional details regarding the Company’s joint development agreement (“JDA”) with Augmenta Bioworks, Inc. (“Augmenta”). If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers
Research and Development Tax Incentive	Research and Development Tax Incentive The Company is eligible to obtain a cash refund from the Australian Taxation Office for eligible research and development expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during 2020 as other income in the condensed consolidated statements of operations during the period ended September 30, 2021. As the Company has determined that it has reasonable assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company’s ongoing tax status, or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for the periods ended September 30, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the IRS related to research and development tax credits for expenditures. The research and development incentive receivable represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development tax incentive receivable of $949,168 and $966,646 as of September 30, 2022 and December 31, 2021, respectively, in the condensed consolidated balance sheets. The Company recorded other income (expense) of $(13,129) and $659,695, in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021, respectively, related to refundable research and development incentive program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $25,544 and $103,307 during the three and nine months ended September 30, 2022, respectively, and $219,520 and $735,927 during the three and nine months ended September 30, 2021, respectively.
Basic and Diluted Earnings per Common Share	Basic and Diluted Earnings per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. For the nine months ended September 30, 2022 and 2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted net loss per common share because inclusion thereof would be anti-dilutive:
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.
Recent Accounting Standards	Recent Accounting Standards There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the nine months ended September 30, 2022 that are of significance or potential significance to the Company.
Risks and Uncertainties	Risks and Uncertainties In December 2019, COVID-19, a novel strain of coronavirus, was first identified in China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Potential impacts to the Company’s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the supply of comparator products, the potential diversion of healthcare resources and staff away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company’s ability to raise capital and conduct business development activities. The Company has experienced COVID-19 related delays in its Phase 2 clinical trials for TFF Voriconazole Inhalation Powder (“TFF Vori”) and TFF Tacrolimus Inhalation Powder (“TFF Tac-Lac”). While the Company believes it will be able to effectively manage the delays, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Organization and Description of Business [Abstract]
Schedule of potential common stock equivalents outstanding	Nine Months Ended September 30, 2022 2021 Stock Options 2,866,439 2,723,339 Warrants 414,233 389,233 3,280,672 3,112,572

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of supplemental balance sheet information related to leases	September 30, Operating leases:  Operating lease right-of-use assets $ 214,264 Operating lease liability – current portion $ 79,838 Operating lease liability – long-term portion 128,314 Total operating lease liabilities $ 208,152
Schedule of supplemental lease expense related to leases	Statement of Operations For The Three Months Ended September 30, For The Nine Months Ended September 30, Lease Classification 2022 2021 2022 2021 Operating lease cost Research and development $ 22,275 $ - $ 29,700 $ - Short-term lease cost Research and development 6,244 11,000 18,733 27,000 Short-term lease cost General and administrative 21,000 9,000 62,659 27,000 Total lease expense $ 49,519 $ 20,000 $ 111,092 $ 54,000
Schedule of other information related to operating leases	September 30, Weighted-average remaining lease term 2.7 years Weighted-average discount rate 8 %
Schedule of supplemental cash flow information related to operating leases	For The Nine Months Ended September 30, 2022 2021 Cash paid for operating lease liabilities $ 29,869 $ -
Schedule of future minimum lease payments under non-cancellable leases (including short-term leases)	Fiscal Year Ending December 31, 2022 (Remaining) $ 24,000 2023 119,000 2024 91,000 2025 38,000 Total minimum lease payments 272,000 Less: Imputed interest (23,000 ) Total $ 249,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation [Abstract]
Schedule of stock-based compensation expense	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ 228,170 $ 137,549 $ 676,053 $ 274,285 General and administrative 727,391 719,045 2,652,291 2,353,259 $ 955,561 $ 856,594 $ 3,328,344 $ 2,627,544
Schedule of fair value of stock options	Nine Weighted average exercise price $ 7.06 Weighted average grant date fair value $ 5.34 Assumptions Expected volatility 90%-97 % Weighted average expected term (in years) 6.3-10.0 Risk-free interest rate 2.41%-2.84 % Expected dividend yield 0.00 %
Schedule of stock option activity	Number of Weighted- Weighted- Intrinsic Outstanding at January 1, 2022 2,893,839 $ 6.48 8.05 $ 9,932,413 Granted 135,000 7.06 — — Exercised (42,292 ) 2.62 — — Cancelled (120,108 ) 7.44 — — Outstanding at September 30, 2022 2,866,439 $ 6.53 7.41 $ 1,186,091 Exercisable at September 30, 2022 1,770,913 $ 5.37 6.88 $ 1,138,945

Liquidity and Management_s Pl_2

Liquidity and Management’s Plans (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Jun. 10, 2022
Liquidity And Managements Plans Abstract
Net loss	$ 7.3	$ 24.4
Cash flow from operation	19.6	19.6
Cash and cash equivalents	89.7	89.7
Working capital	$ 13.1	$ 13.1
Aggregate offering price			$ 35
Common stock shares, description		Through September 30, 2022, the Company sold 104,011 shares of its common stock at average price of $5.96 per share resulting in net proceeds of approximately $405,000, after deducting sales agent commissions and offering expenses.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 AUD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 AUD ($)
Summary of Significant Accounting Policies (Details) [Line Items]
Cash	$ 38,376		$ 38,376		$ 59,664	$ 604,944	$ 831,984
Research and development expenses	87,586	$ 50,000	183,025	$ 76,165
Prepaid assets and other current assets	232,296		232,296			11,996
Deferred grant revenue	362,710		$ 362,710			50,000
Research and development tax percentage			43.50%	43.50%
Other income (expense)		(13,129)		$ 659,695
Research and Development [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Research and development tax incentive	949,168		$ 949,168			$ 966,646
Other income (expense)		(13,129)		659,695
Research and Development Expense [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Research and development expenses	$ 25,544	$ 219,520	$ 103,307	$ 735,927

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]
Potential common stock equivalents outstanding	3,280,672	3,112,572
Warrants [Member]
Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]
Potential common stock equivalents outstanding	414,233	389,233
Stock Options [Member]
Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]
Potential common stock equivalents outstanding	2,866,439	2,723,339

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	1 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Subsequent Event [Member]
Commitments and Contingencies (Details) [Line Items]
Rent expenses		$ 36,000
Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Rent expenses	$ 37,080

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to leases	9 Months Ended
	Sep. 30, 2022 USD ($)
Operating leases:
Operating lease right-of-use assets	$ 214,264
Operating lease liability – current portion	79,838
Operating lease liability – long-term portion	128,314
Total operating lease liabilities	$ 208,152

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of supplemental lease expense related to leases - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total lease expense	$ 49,519	$ 20,000	$ 111,092	$ 54,000
Research and development [Member]
Segment Reporting Information [Line Items]
Operating lease cost	22,275		29,700
Short-term lease cost	6,244	11,000	18,733	27,000
General and administrative [Member]
Segment Reporting Information [Line Items]
Short-term lease cost	$ 21,000	$ 9,000	$ 62,659	$ 27,000

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of other information related to operating leases	Sep. 30, 2022
Schedule Of Other Information Related To Operating Leases Abstract
Weighted-average remaining lease term	2 years 8 months 12 days
Weighted-average discount rate	8%

Commitments and Contingencies_6

Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to operating leases - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule Of Supplemental Cash Flow Information Related To Operating Leases Abstract
Cash paid for operating lease liabilities	$ 29,869

Commitments and Contingencies_7

Commitments and Contingencies (Details) - Schedule of future minimum lease payments under non-cancellable leases	Sep. 30, 2022 USD ($)
Schedule Of Future Minimum Lease Payments Under Non Cancellable Leases Abstract
2022 (Remaining)	$ 24,000
2023	119,000
2024	91,000
2025	38,000
Total minimum lease payments	272,000
Less: Imputed interest	(23,000)
Total	$ 249,000

License and Agreements (Details

License and Agreements (Details) - USD ($)		1 Months Ended			3 Months Ended		9 Months Ended
	Aug. 12, 2020	May 31, 2020	Jan. 31, 2020	Jan. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Nov. 24, 2019	Mar. 31, 2018
License and Agreements (Details) [Line Items]
Assignment fee											$ 100,000
Milestone payment										$ 50,000
Accounts payable due					$ 0		$ 0		$ 21,000
Recorded research and development costs					4,025,940	$ 6,339,993	14,360,293	$ 14,380,415
Pre-marketing approvals	$ 25,000,000
Interest fee							500,000
Research and development expenses					0	341,840	184,273	828,511
Other receivable					1,812,975		1,812,975		1,628,703
ITR [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					0		0		$ 0
April 2019 [Member]
License and Agreements (Details) [Line Items]
Recorded research and development costs					209,000	639,000	835,000	1,436,000
January 2021 [Member]
License and Agreements (Details) [Line Items]
Recorded research and development costs					643,000	735,000	1,223,000	1,036,000
January 2022 [Member]
License and Agreements (Details) [Line Items]
Recorded research and development costs					800,000		2,099,000
Master Services Agreement [Member]
License and Agreements (Details) [Line Items]
Agreement term, description				In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.
Recorded research and development costs					41,000		2,358,000
Master Services Agreement [Member] | Contract Manufacturing Services [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					363,000		363,000
Recorded research and development costs						$ 0		$ 2,380,000
Master Services Agreement [Member] | January 2021 [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					$ 133,000		$ 133,000
Clinical Network Services Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Agreement description			In January 2020, TFF Australia entered into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$38,000 (US$24,000) and AUD$138,000 (US$100,000) as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately AUD$87,000 (US$59,000) and AUD$550,000 (US$388,000), respectively, pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately AUD$547,000 (US$402,000) and AUD$1,468,000 (US$1,113,000), respectively, pertaining to this agreement
Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Agreement description		In May 2020, TFF Australia entered into an amended clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company’s drug candidates, TFF Tac-Lac. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company did not record any research and development costs pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately AUD$119,000 (US$87,000) and AUD$565,000 (US$429,000), respectively, pertaining to this agreement.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Jun. 10, 2022
STOCKHOLDERS' EQUITY [Abstract]
Shares of common stock (in Shares)	42,292
Total proceeds	$ 110,822
Prepaid asset and other current assets	$ 100,637
Aggregate offering price		$ 35,000,000
Common stock average price, description	Through September 30, 2022, the Company sold 104,011 shares of its common stock at average price of $5.96 per share resulting in net proceeds of approximately $405,000, after deducting offering expenses.

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)		1 Months Ended		9 Months Ended
	Jun. 07, 2022	Sep. 30, 2021	Jan. 31, 2018	Sep. 30, 2022
Stock-Based Compensation [Abstract]
Reserved shares		4,200,000	1,630,000
IPO shares			3,284,480
Outstanding percentage			15%
Unrecognized compensation expense				$ 6,708,000
Weighted-average period				1 year 10 months 24 days
Intrinsic value				$ 76,000
General and administrative				$ 339,000
Warrant, description	the Company issued a five-year warrant to purchase 25,000 shares of common stock at $5.70 per share to a consultant. The fair value of the warrant on the grant date was estimated using the Black-Scholes-Merton option pricing model with a common stock value of $5.74 per share, a contractual life of 5.0 years, a dividend yield of 0%, volatility of 96.87% and an assumed risk-free interest rate of 2.99%. The warrant is immediately exercisable. The fair value of the warrant was determined to be approximately $107,000 and was recorded in general and administrative expenses in the condensed consolidated statements of operations during the period ended September 30, 2022.

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Stock based compensation expense	$ 955,561	$ 856,594	$ 3,328,344	$ 2,627,544
Research and development [Member]
Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Stock based compensation expense	228,170	137,549	676,053	274,285
General and administrative [Member]
Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Stock based compensation expense	$ 727,391	$ 719,045	$ 2,652,291	$ 2,353,259

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of fair value of stock options	9 Months Ended
	Sep. 30, 2022 $ / shares
Stock-Based Compensation (Details) - Schedule of fair value of stock options [Line Items]
Weighted average exercise price (in Dollars per share)	$ 7.06
Weighted average grant date fair value (in Dollars per share)	$ 5.34
Assumptions
Expected dividend yield	0%
Minimum [Member]
Assumptions
Expected volatility	90%
Weighted average expected term (in years)	6 years 3 months 18 days
Risk-free interest rate	2.41%
Maximum [Member]
Assumptions
Expected volatility	97%
Weighted average expected term (in years)	10 years
Risk-free interest rate	2.84%

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of stock option activity - USD ($)	9 Months Ended
	Sep. 30, 2022
Schedule Of Stock Option Activity Abstract
Number of Shares, Outstanding, Outstanding ending balance	2,893,839
Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance (in Dollars per share)	$ 6.48
Weighted-Average Remaining Contractual Term, Outstanding ending balance	8 years 18 days
Intrinsic Value, Outstanding ending balance (in Dollars)	$ 9,932,413
Number of Shares, Outstanding, Granted	135,000
Weighted-Average Exercise Prices, Outstanding, Granted (in Dollars per share)	$ 7.06
Weighted-Average Remaining Contractual Term, Granted
Intrinsic Value, Granted (in Dollars)
Number of Shares, Outstanding, Exercised (in Dollars per share)	$ (42,292)
Weighted-Average Exercise Prices, Outstanding, Exercised (in Dollars per share)	$ 2.62
Weighted-Average Remaining Contractual Term, Exercised
Intrinsic Value, Exercised
Number of Shares, Outstanding, Exercised	(120,108)
Weighted-Average Exercise Prices, Outstanding, Exercised	7.44
Weighted-Average Remaining Contractual Term, Exercised
Intrinsic Value, Exercised (in Dollars)
Number of Shares, Outstanding, Outstanding ending balance	2,866,439
Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance (in Dollars per share)	$ 6.53
Weighted-Average Remaining Contractual Term, Outstanding ending balance	7 years 4 months 28 days
Intrinsic Value, Outstanding ending balance (in Dollars)	$ 1,186,091
Number of Shares, Outstanding, Exercisable	1,770,913
Weighted-Average Exercise Prices, Outstanding, Exercisable (in Dollars per share)	$ 5.37
Weighted-Average Remaining Contractual Term, Exercisable	6 years 10 months 17 days
Intrinsic Value, Exercisable (in Dollars)	$ 1,138,945